Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Xenon ( (XENE) ) has shared an update.
Xenon Pharmaceuticals reported its second quarter 2025 financial results and provided a business update, highlighting the completion of patient recruitment for the Phase 3 X-TOLE2 study of azetukalner, with topline data expected in early 2026. The company is advancing its Phase 3 programs for azetukalner in neuropsychiatric disorders, including MDD and BPD, and is conducting early-stage studies on ion channel modulators for pain. Financially, Xenon reported a net loss of $84.7 million for the quarter, attributed to increased research and development expenses, particularly for the azetukalner program.
The most recent analyst rating on (XENE) stock is a Buy with a $63.00 price target. To see the full list of analyst forecasts on Xenon stock, see the XENE Stock Forecast page.
Spark’s Take on XENE Stock
According to Spark, TipRanks’ AI Analyst, XENE is a Neutral.
Xenon’s primary strengths lie in its strong financial position and positive clinical development progress, as highlighted in the earnings call. However, the absence of revenue and profitability, along with technical and valuation concerns, weigh heavily on the overall stock score.
To see Spark’s full report on XENE stock, click here.
More about Xenon
Xenon Pharmaceuticals Inc. is a neuroscience-focused biopharmaceutical company engaged in drug discovery, clinical development, and commercialization of therapeutics for patients with neurological disorders. The company is involved in developing treatments for epilepsy, major depressive disorder (MDD), bipolar depression (BPD), and pain, leveraging its expertise in potassium and sodium channel therapeutics.
Average Trading Volume: 1,257,998
Technical Sentiment Signal: Sell
Current Market Cap: $2.57B
For a thorough assessment of XENE stock, go to TipRanks’ Stock Analysis page.